GlaxoSmithKline Pakistan - Public Comps and Valuation Multiples

GlaxoSmithKline Pakistan Overview

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.

Founded

2001

HQ

Employees

1.7K+

Website

pk.gsk.com

Sectors

Drug Development & Therapeutics
Vaccines & Immunotherapies
BioTech

Financials

LTM Revenue $218M

Last FY EBITDA $41.6M

EV

$426M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

GlaxoSmithKline Pakistan Financials

As of November 2025, GlaxoSmithKline Pakistan reported last 12-month revenue of $218M.

In the same period, GlaxoSmithKline Pakistan generated $54.9M in LTM gross profit and $23.3M in net income.

See GlaxoSmithKline Pakistan valuation multiples based on analyst estimates

GlaxoSmithKline Pakistan P&L

In the most recent fiscal year, GlaxoSmithKline Pakistan reported revenue of $218M and EBITDA of $41.6M.

GlaxoSmithKline Pakistan expects next 12-month revenue of XXX and NTM EBITDA of XXX

See GlaxoSmithKline Pakistan valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$218M	XXX	$218M	XXX	XXX	XXX
Gross Profit	$54.9M	XXX	$54.9M	XXX	XXX	XXX
Gross Margin	25%	XXX	25%	XXX	XXX	XXX
EBITDA	n/a	XXX	$41.6M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	19%	XXX	XXX	XXX
EBIT	$31.7M	XXX	$36.2M	XXX	XXX	XXX
EBIT Margin	15%	XXX	17%	XXX	XXX	XXX
Net Profit	$23.3M	XXX	$23.3M	XXX	XXX	XXX
Net Margin	11%	XXX	11%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for GlaxoSmithKline Pakistan including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $218M. In the most recent fiscal year, GlaxoSmithKline Pakistan achieved $218M in revenue and $41.6M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$218M	Analyst estimates available to subscribers	$218M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$54.9M	Analyst estimates available to subscribers	$54.9M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	25.1% gross margin	Analyst estimates available to subscribers	25.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	$41.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	19.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$31.7M	Analyst estimates available to subscribers	$36.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	14.5% EBIT margin	Analyst estimates available to subscribers	16.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$23.3M	Analyst estimates available to subscribers	$23.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	10.7% net profit margin	Analyst estimates available to subscribers	10.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for GlaxoSmithKline Pakistan

This financial data table provides comprehensive performance metrics for GlaxoSmithKline Pakistan, a company based in Pakistan. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

GlaxoSmithKline Pakistan generated $218M in revenue over the last twelve months.
Gross profit for the last twelve months was $54.9M.
Net income over the last twelve months reached $23.3M.

Fiscal Year Performance

In the most recent fiscal year, GlaxoSmithKline Pakistan reported $218M in total revenue.
Fiscal year EBITDA was $41.6M.
The company maintained a gross profit margin of 25.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 19.0%.
Net profit margin reached 10.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for GlaxoSmithKline Pakistan. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

GlaxoSmithKline Pakistan Stock Performance

GlaxoSmithKline Pakistan has current market cap of PKR 126B (or $449M), and EV of PKR 119B (or $426M).

Market Cap Evolution

GlaxoSmithKline Pakistan Stock Data

As of December 3, 2025, GlaxoSmithKline Pakistan's stock price is PKR 395 (or $1).

See GlaxoSmithKline Pakistan trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$426M	$449M	XXX	XXX	XXX	XXX	$0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

GlaxoSmithKline Pakistan Valuation Multiples

GlaxoSmithKline Pakistan's trades at 1.9x EV/Revenue multiple, and 10.2x EV/EBITDA.

See valuation multiples for GlaxoSmithKline Pakistan and 15K+ public comps

GlaxoSmithKline Pakistan Financial Valuation Multiples

As of December 3, 2025, GlaxoSmithKline Pakistan has market cap of $449M and EV of $426M.

Equity research analysts estimate GlaxoSmithKline Pakistan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

GlaxoSmithKline Pakistan has a P/E ratio of 19.3x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$449M	XXX	$449M	XXX	XXX	XXX
EV (current)	$426M	XXX	$426M	XXX	XXX	XXX
EV/Revenue	1.9x	XXX	1.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	10.2x	XXX	XXX	XXX
EV/EBIT	13.4x	XXX	11.8x	XXX	XXX	XXX
EV/Gross Profit	7.8x	XXX	n/a	XXX	XXX	XXX
P/E	19.3x	XXX	19.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	52.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get GlaxoSmithKline Pakistan Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

GlaxoSmithKline Pakistan Margins & Growth Rates

GlaxoSmithKline Pakistan's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $11K for the same period.

GlaxoSmithKline Pakistan's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

GlaxoSmithKline Pakistan's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for GlaxoSmithKline Pakistan and other 15K+ public comps

GlaxoSmithKline Pakistan Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	19%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$11K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	4%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	9%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial